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CORRESPONDENCE
The burden and pharmacoeconomics of epilepsy in
India
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Epilepsy affects 40 million people worldwide, three-
quarters of whom remain untreated. About 75% of the
40 million people with epilepsy worldover are in de-
veloping countries. However, with early diagnosis and
treatment, epilepsy can be controlled in three-quarters
of those affected1. Since the prevalence rate of ac-
tive epilepsy in India is 5.5/1000, the number of ac-
tive epilepsy patients in India will amount to 5.4 mil-
lion, i.e. one-eighth of the total epilepsy patients in the
world2.
A recent meta-analysis, conducted by Sreedharan
and Murthy3, estimated that the number of people with
epilepsy by the year 2001 will be 5.5 million and the
number of new cases of epilepsy every year as approx-
imately half a million. Since 74% of the Indian popula-
tion live in rural areas, the number of rural epilepsy pa-
tients would be∼ 4.1 million, out of which∼ 3.0 mil-
lion will not be getting any treatment for epilepsy! The
above statistics clearly shows the enormous burden of
epilepsy for a developing country, like India, where
the Gross National Product (GNP) per capita income is
only US$ 390 (US$ 1= Indian Rupees 43.0), whereas,
the GNP per capita for United Kingdom (UK) and
the United States of America (USA) are US$ 20 710
and 28 740 respectively4. Hence, there is an emer-
gent need for an appropriate choice of antiepileptic
drug (AED) for each epilepsy syndrome. Moreover,
the emphasis should be on the choice of inexpensive
AEDs like phenobarbital (PB) and phenytoin (DPH)
over carbamazepine (CBZ) wherever possible, start-
ing as monotherapy, based on the International League
Against Epilepsy (ILAE) classification5.
Intractable epilepsy is most often the result of
missed opportunities for therapy6. Sub-optimal use of
antiepileptic drugs, non-compliance, inappropriate se-
lection of AEDs, wrong AED for a wrong diagnosis,
polypharmacy etc. can result in escalation of cost and
intractability.
Following the era of widespread polytherapy for the
treatment of epilepsy, it is now uniformly accepted that
most cases of newly diagnosed epilepsy in children or
adults can be controlled with a single AED7–10. Evi-
dence has accumulated in the literature that the correct1059–1311/99/070436 + 02 $12.00/0election of drug in the appropriate dose remains the
ornerstone of treatment of epilepsy, toxicity and cost
eing an important consideration in this decision11.
he affordability of medical care is a significant fac-
or in choice of AEDs not only in the developing
ations, but also in developed countries where medi-
al accountability prevails. The pursuit of efficiency in
ealth-care demands priority to be given to those treat-
ents which provide the best benefit per unit of cost12.
he education of patients regarding the importance
f compliance and periodic drug level estimations
re also important in the management of epilepsy13.
olypharmacy and frequent use of comparatively ex-
ensive AEDs such as CBZ and valproate (VPA) have
scalated the cost of treatment in developing countries
uch as India. In addition, less expensive drugs such as
B and DPH remain under-utilized in our country14.
In this context, it will be prudent to consider stud-
es on the efficacy of various AEDs in patients with
imilar seizure semiology. The drug of choice for ab-
ence seizures, juvenile myoclonic epilepsy and other
rimary generalized epilepsies, is VPA15. In a ran-
omized comparative monotherapy trial of PB, DPH,
BZ and VPA in newly diagnosed childhood epilepsy,
e Silva et al. 16 concluded that the overall out-
ome with all four drugs was good. There was no
ignificant difference in efficacy between the drugs
or these seizure types. One hundred and sixty-seven
hildren aged 3–16 years, who had at least two pre-
iously untreated generalized tonic–clonic (GTC) or
artial seizures, with or without secondary generaliza-
ion (P±GTC) were included in the study. Children
ith any other type of seizure (e.g. absence, myoclonic
erks and drop attacks) were excluded from this study.
he overall frequency of unacceptable side-effects ne-
essitating withdrawal of drug was 9%. This included
of the first 10 children assigned PB; no further chil-
ren were allocated this drug. Of the remaining three
rugs, DPH was more likely to be withdrawn (9%)
han CBZ (4%) and VPA (4%). These authors con-
luded that the choice of first AED for such children
ill be influenced largely by toxicity and cost.
Mattson et al. 17, in a comprehensive study, noted
hat all the four AEDs (viz. CBZ, PB, DPH and prim-c© 1999 BEA Trading Ltd
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ily generalized tonic–clonic seizures. Since DPH and
CBZ shared similar rates of adverse effects, the choice
between them will depend on the prolonged half life
and lower cost of the former. In another randomized
comparative monotherapy trial from UK, Heller et al.
18 concluded that overall outcome with the four drugs,
viz. PB, DPH, CBZ or VPA, was good. No signifi-
cant differences were found between the four drugs for
measure of efficacy. These authors re-iterated that con-
siderations of toxicity and costs influenced the choice
of drug. In this study, the incidence of unacceptable
side effects necessitating withdrawal was more often
for PB (22%) followed by CBZ (11%), VPA (5%) and
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In the United States, DPH continues to be the most
commonly used AED (48%)19, whereas in India, DPH
and CBZ are used in about 25% and 44% of pa-
tients, respectively. In India, an average patient treated
with PB, DPH, CBZ or VPA as monotherapy would
spend 4.4, 7.1, 16.8 and 29.5% of gross national prod-
uct per inhabitant (GNP/Capita) respectively14.
Therefore, in a country like India where the bur-
den of epilepsy is tremendous and the need for cost-
containment is pressing, DPH appears to be a better
choice over CBZ and VPA, which I believe, would also
reinforce better compliance, in the majority of people
with epilepsy with partial, with or without secondary
generalized, seizures. Judicious selection and use of
antiepileptic drugs aided by advances in clinical neu-
rophysiological testing modalities including electroen-
cephalography (EEG), digital/video EEG and newer
modes of therapy with epilepsy surgery and vagal
nerve stimulation will go a long way in enhancing suc-
cess in managing patients with epilepsy in developing
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